A randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

Psychopharmacology Bulletin

Volumn 45, Issue 1, 2012, Pages 5-30

  Wang, Gang ^a   McIntyre, Alexander ^b   Earley, Willie R ^c   Raines, Shane ^c   Eriksson, Hans ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Penticton Regional Hospital   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Antidepressive agents pharmacological action ; Antipsychotic agents; Clinical trial; Controlled clinical trial; Multicenter study; Phase III; Sustained release preparations; Treatment efficacy

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESCITALOPRAM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUETIAPINE; QUETIAPINE XR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATION; ANXIETY; ARTHRALGIA; ARTICLE; CHILL; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CRYING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERSOMNIA; INCREASED APPETITE; INFLUENZA; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MOOD CHANGE; MUSCLE TONE; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; POLYURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SWEATING; THIRST; UNPLEASANT DREAM; UPPER ABDOMINAL PAIN; VIVID DREAM; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84864669165     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003; 25:2289-2304.
2. Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv. 2008;46:21-24.
3. AstraZeneca. Seroquel XR-Summary of Product Characteristics for Ireland. Available at: http://www.medicines.ie/medicine/13032/SPC/Seroquel_XR_50mg%2c_150mg%2c_200mg%2c _300mg%2c_400mg_prolonged-release_tablets/. Accessed: 11/14/2011.
4. AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets/US prescribing information. Available at: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed: 11/14/2011.
5. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128:83-94.
6. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry. 2009;70:526-539.
7. Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299-313.
8. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, doubleblind study. J Clin Psychiatry. 2009;70:540-549.
9. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917-932.
10. Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebocontrolled trial. Depress Anxiety. 2010;27:964-976.
11. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. In press.
12. Glick ID, Suppes T, DeBattista C, et al. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med. 2001;134:47-60.
13. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSMIV and ICD-10. J Clin Psychiatry. 1998;59 (Suppl 20):22-33.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
15. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
16. Forest Pharmaceuticals, Inc. Escitalopram prescribing information. Available at: http://www.frx.com/ pi/lexapro_pi.pdf. Accessed: 5/1/2011.
17. National Institutes of Mental Health. CGI: Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery. Chevy Chase: NIMH; 1970:1-6.
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
19. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321-326.
20. Buysse DJ, Reynolds CF, III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213.
21. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
22. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
23. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731-745.
24. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363-368.
25. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77-87.
26. Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol. 2005;6:221-226.
27. Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005;5:1077-1086.
28. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115-127.
29. Kobak KA, Kane JM, Thase ME, et al. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27:1-5.
30. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34-40.
31. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159:191-200.
32. Stein DJ, Baldwin DS, Dolberg OT, et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67:1741-1746.
33. FDA. Antidepressant use in children, adolescents and adults. Available at: http://www.fda.gov/ cder/drug/antidepressants/default.htm. Accessed: 5/1/2011.
34. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.